Inhibitory monoclonal antibody targeting ADAM17 expressed on cancer cells

ADAM17 is upregulated in many cancers and in turn activates signaling pathways, including EGFR/ErbB, as well as those underlying resistance to targeted anti-EGFR therapies. Due to its central role in oncogenic pathways and drug resistance mechanisms, specific and efficacious monoclonal antibodies ag...

Descripción completa

Detalles Bibliográficos
Autores principales: Saha, Nayanendu, Xu, Kai, Zhu, Zhongyu, Robev, Dorothea, Kalidindi, Teja, Xu, Yan, Himanen, Juha, de Stanchina, Elisa, Pillarsetty, Naga Vara Kishore, Dimitrov, Dimiter S, Nikolov, Dimitar B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8592942/
https://www.ncbi.nlm.nih.gov/pubmed/34768098
http://dx.doi.org/10.1016/j.tranon.2021.101265

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8592942/
https://www.ncbi.nlm.nih.gov/pubmed/34768098
http://dx.doi.org/10.1016/j.tranon.2021.101265

Ejemplares similares